Skip to content

Study · Non-randomized trial · 2015

4 results

Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes.

von Scholten BJ, Hansen TW, Goetze JP, Persson F, Rossing P

Journal of diabetes and its complications11 Apr 2015Cited by 53 (Europe PMC)

PMID25935863 (opens in a new tab)DOI10.1016/j.jdiacomp.2015.04.004 (opens in a new tab)PepBankPUB-25935863
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes, long-term liraglutide treatment reduced measured GFR by 11 mL/min/1.73 m2 from baseline.

    In plain wordsIn adults with type 2 diabetes, a year of liraglutide was linked to a reversible fall in kidney filtration rate.

    Peptide
    Liraglutide
    Outcome
    DecreaseGlomerular filtration rate (GFR) change
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · one-year extensionAs given in this study (human).

    Measurements

    GFR change
    −11 mL/min/1.73 m(2)
    liraglutide

    Source sentences

    Summary
    Baseline GFR was 100.6 (24.9) mL/min/1.73 m(2) and was reduced by 11 (95% CI: 6.6-15.7, p < 0.001) mL/min/1.73 m(2), independent of change in 24-h systolic blood pressure (SBP), weight, UAER or HbA(1c) (p≥0.33).
    3 context sentences
    Summary · context
    Primary outcome was change in GFR ((51)Cr-EDTA plasma clearance).
    Summary · context
    We included 30 patients in a one-year extension study, all initially treated with liraglutide for seven weeks.
    Summary · context
    During follow-up 23 were treated with liraglutide and seven untreated.
  2. 02HumanNon-randomized trialMechanism

    In adults with type 2 diabetes on liraglutide, the GFR reduction was independent of changes in 24-h systolic blood pressure, weight, UAER or HbA1c.

    In plain wordsOn liraglutide, the fall in kidney filtration was not explained by changes in blood pressure, weight, urine albumin or HbA1c.

    Peptide
    Liraglutide
    Outcome
    Not applicableGFR reduction independent of changes in SBP, weight, UAER or HbA1c
    Study

    n: not reported in source

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · one-year extensionAs given in this study (human).

    Source sentences

    Summary
    independent of change in 24-h systolic blood pressure (SBP), weight, UAER or HbA(1c) (p≥0.33).
    2 context sentences
    Summary · context
    We included 30 patients in a one-year extension study, all initially treated with liraglutide for seven weeks.
    Summary · context
    During follow-up 23 were treated with liraglutide and seven untreated.
  3. 03HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes, long-term liraglutide treatment reduced the urinary albumin excretion rate by 27%.

    In plain wordsIn adults with type 2 diabetes, a year of liraglutide was linked to less albumin in the urine.

    Peptide
    Liraglutide
    Outcome
    DecreaseUrinary albumin excretion rate (UAER) change
    Study

    n: not reported in source

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · one-year extensionAs given in this study (human).

    Measurements

    UAER reduction
    27%
    liraglutide

    Source sentences

    Summary
    Geometric mean (IQR) of UAER was 25.5 (9.9-50.9) mg/d and was reduced by 27 (95% CI: 5-44; p = 0.020)%
    2 context sentences
    Summary · context
    We included 30 patients in a one-year extension study, all initially treated with liraglutide for seven weeks.
    Summary · context
    During follow-up 23 were treated with liraglutide and seven untreated.
  4. 04HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes, long-term liraglutide treatment reduced 24-h systolic blood pressure by 8.2 mmHg.

    In plain wordsIn adults with type 2 diabetes, a year of liraglutide was linked to lower 24-hour systolic blood pressure.

    Peptide
    Liraglutide
    Outcome
    Decrease24-h systolic blood pressure change
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · one-year extensionAs given in this study (human).

    Measurements

    24-h systolic blood pressure reduction
    8.2 mmHg
    liraglutide

    Source sentences

    Summary
    and 24-h SBP was reduced by 8.2 (p = 0.048) mmHg.
    2 context sentences
    Summary · context
    We included 30 patients in a one-year extension study, all initially treated with liraglutide for seven weeks.
    Summary · context
    During follow-up 23 were treated with liraglutide and seven untreated.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT01499108

Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes

Peter Rossingn = 32Aug 2012 to Aug 2014

Type 2 Diabetes

Trial pageClinicalTrials.govUpdated 2 Feb 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.